Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease
Stevens–Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn’s disease who developed S...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Gastrointestinal Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/3875024 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560707150807040 |
|---|---|
| author | Jenny Roselli Tommaso Innocenti Erica Nicola Lynch Laura Parisio Pasquale Apolito Tommaso Mello Giuseppe Macrì Monica Milla Maria Rosa Biagini Mirko Tarocchi Stefano Milani Andrea Galli |
| author_facet | Jenny Roselli Tommaso Innocenti Erica Nicola Lynch Laura Parisio Pasquale Apolito Tommaso Mello Giuseppe Macrì Monica Milla Maria Rosa Biagini Mirko Tarocchi Stefano Milani Andrea Galli |
| author_sort | Jenny Roselli |
| collection | DOAJ |
| description | Stevens–Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn’s disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNFα therapy with adalimumab. Remission was achieved with suspension of adalimumab and high doses of intravenous steroids and antivirals. Patients with HSV1 infection and on adalimumab therapy have a combined risk of SJS and should be monitored closely. |
| format | Article |
| id | doaj-art-f308cf6d9ec948cf81cfeb8d1127bda6 |
| institution | Kabale University |
| issn | 2090-6528 2090-6536 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Gastrointestinal Medicine |
| spelling | doaj-art-f308cf6d9ec948cf81cfeb8d1127bda62025-02-03T01:26:58ZengWileyCase Reports in Gastrointestinal Medicine2090-65282090-65362020-01-01202010.1155/2020/38750243875024Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s DiseaseJenny Roselli0Tommaso Innocenti1Erica Nicola Lynch2Laura Parisio3Pasquale Apolito4Tommaso Mello5Giuseppe Macrì6Monica Milla7Maria Rosa Biagini8Mirko Tarocchi9Stefano Milani10Andrea Galli11Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyAzienda Ospedaliero-Universitaria Careggi, Florence, ItalyAzienda Ospedaliero-Universitaria Careggi, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, ItalyStevens–Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn’s disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNFα therapy with adalimumab. Remission was achieved with suspension of adalimumab and high doses of intravenous steroids and antivirals. Patients with HSV1 infection and on adalimumab therapy have a combined risk of SJS and should be monitored closely.http://dx.doi.org/10.1155/2020/3875024 |
| spellingShingle | Jenny Roselli Tommaso Innocenti Erica Nicola Lynch Laura Parisio Pasquale Apolito Tommaso Mello Giuseppe Macrì Monica Milla Maria Rosa Biagini Mirko Tarocchi Stefano Milani Andrea Galli Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease Case Reports in Gastrointestinal Medicine |
| title | Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease |
| title_full | Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease |
| title_fullStr | Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease |
| title_full_unstemmed | Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease |
| title_short | Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease |
| title_sort | stevens johnson syndrome and herpes simplex type 1 infection during adalimumab therapy for crohn s disease |
| url | http://dx.doi.org/10.1155/2020/3875024 |
| work_keys_str_mv | AT jennyroselli stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT tommasoinnocenti stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT ericanicolalynch stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT lauraparisio stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT pasqualeapolito stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT tommasomello stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT giuseppemacri stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT monicamilla stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT mariarosabiagini stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT mirkotarocchi stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT stefanomilani stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease AT andreagalli stevensjohnsonsyndromeandherpessimplextype1infectionduringadalimumabtherapyforcrohnsdisease |